Scott Braunstein, Marinus Pharmaceuticals CEO
Marinus reports mixed Phase 3 results on IV seizure drug
Marinus Pharmaceuticals reported Monday that its IV drug met only one of two key endpoints in a Phase 3 study for prolonged seizures.
In the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
